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CHAPTER I
INTRODUCTION
In vitro studies in our laboratory (1,2) and elsewhere
(3,4) have shown that dopamine can directly stimulate renin
release from the mammalian renal juxtaglomerular cells and
that this effect appears to be mediated by a beta-adrenergic
receptor mechanism involving increases in tissue cyclic AMP
levels (1,2).

We have also evaluated the possibility that

dopamine-specific receptors may participate in the regulation of renin secretion {1,2).

In these studies, the dop-

amine-receptor blocking agent, pimozide, significantly stimulated renin secretion from renal cortical slices of sodium
deficient rats.

This marked increase in renin secretion

occured whether or not dopamine was added in conjunction with
this agent, suggesting that the stimulatory effect is due to
pimozide itself.

Furthermore, the observed increase in renin

secretion in response to various doses of pimozide was
coupled with a significant decrease in tissue cyclic AMP
content after a one hour incubation period.

These data sug-

gest an inhibitory action of dopamine or renin release which

is prevented by administration of pimozide.

Conversely,

these results could reflect a generalized effect of pimozide
1

2
on the juxtaglomerular cell membrane resulting in uncontrolled release of pre-formed renin.

Clearly, further studies

are required in order to fully evaluate the type of mechanism by which pimozide itself influences renin secretion, and
to further examine the possibility that dopaminergic receptors may participate in the regulation of renin release.
~

vitro renal tissue preparations are particularly use-

ful in the examination of specific factors which may directly
affect renin release since they effectively eliminate the
action of other factors known to influence renin release in
the live animal.

Furthermore,

~ ~

(5-8) and in vitro

studies {1,2,9-11) have shown that both renin secretion and
the renin secretory responses to sympathetic stimuli, are
potentiated by dietary sodium deprivation.

Thus, a renal

cortical slice preparation from sodium deficient rats which
maximizes juxtaglomerular cell responsiveness, is an effective tool for the evaluation of the mechanisms by which isolated factors regulate renin secretion.
The present study utilizes a hypersensitive renal cortical slice system from the sodium deficient rat to:

1)

determine if the stimulatory effect of dopamine on renin secretion involves the release of pre-formed renin and/or
~

~

synthesis of renin, by examining both secretory and

tissue renin content changes in response to dopamine administration at various time intervals;

2) further evaluate

the possible role of dopaminergic receptors in the regula•
tion of renin release by utilizing the dopamine-receptor

3

agonist, apomorphine;

3) provide additional evidence for a

possible mechanism by which pimozide itself may affect renin
release by examining the changes in tissue renin content,
tissue cyclic AMP levels, and renin secretion rate with time,
in response to administration of this agent to the renal cortical slice system and;

4) further investigate the role of

cyclic AMP as an intracellular mediator by determining if
tissue content responses of this nucleotide are coupled with
changes in tissue renin content and renin release.
Portions of these data have been reported in preliminary form (12).

CHAPTER II
LITERATURE REVIEW
A.

Renin-Angiotensin-Aldosterone Regulation of Electrolyte
and Blood Pressure Homeostasis
Renin, a glycoprotein (13) synthesized in the juxtaglo-

merular cells of the kidney, is normally secreted into the
systemic circulation where it cleaves a hepatic alpha -glo2
bulin angiotensinogen (renin substrate) to form the decapeptide angiotensin I

(13).

Angiotensin I is further split by

the action of a circulating converting enzyme to yield the
powerful vasoconstricting agent angiotensin II (13).

Angio-

tensinase enzymes present in the systemic circulation in
turn inactivate angiotensin II to produce metabolic by-products which possess little or no vasoconstrictor activity
and, are normally excreted in the urine (13).

In addition

to its metabolic fragment angiotensin III, can exert an indirect regulatory effect on blood volume.

Both angiotensin

II and angiotensin III infusions stimulate synthesis and secretion of aldosterone and antidiuretic hormone (ADH), thereby effecting electrolyte and blood volume homeostasis (14-

4

5
16).

Thus, renin, through its effect on angiotensin II and

aldosterone production, is an important factor in the maintenance of electrolyte, blood pressure and blood volume homeostasis.
B.

Control of Renin Secretion
It is well established that renin release in the live

animal, is under the simultaneous influence of a variety of
factors.

These factors include:

1) intrarenal receptors,

such as the afferent arteriole baroreceptor and the macula
densa natrioreceptor;

2) humoral factors such as ADH, angio-

tensin II, estrogen, and intrarenal prostaglandins;

3) cen-

tral nervous system pathways originating in the vasomotor
centers of the medulla oblongata and the hypothalamus;
4)

and

peripheral sympathetic neural mechanisms which are medi-

ated by the renal nerves and circulating catecholamines from
the adrenal medulla.
1.

Intrarenal Receptors
a.

Afferent Arteriole Baroreceptor Control of Renin
Release

The renin-secreting juxtaglomerular cells are modified
smooth muscle cells and as such are sensitive to stretch.
Tobian (17) and Skinner (18) first proposed the existence of
a renal perfusion pressure, asd a number of subsequent studies have confirmed their findings by demonstrating that al-

6

terations in renal blood flow and perfusion pressure can modify renin release.

Utilizing the non-filtering, denervated

kidney in the dog, Blaine and co-workers (19,20) have shown
that the influence of the baroreceptor mechanism can be fully
exerted in the absence of a functional macula densa and the
renal nerves, suggesting that this pathway can operate independently of the other factors which affect renin secretion.
Conversely, infusion of the smooth muscle relaxing agent,
papaverine into the renal artery of the non-filtering dog
kidney (21), have been shown to block the secretory responses
to hemorrhage, further supporting the existence of a vascular
baroreceptor mechanism, participating in the regulation of
renin release.
b.

Macula Densa Control of Renin Release

The close anatomical association between the macula
densa cells of the distal convoluted tubule and the juxtaglomerular cells of the renal afferent arteriole, has led to
the hypothesis that renin release may also be modified by
the electrolyte composition of the filtrate in the distal
tubule.

However, the mechanism by which these changes ul-

timately affect renin release is still under debate.

Studies

by Vander and Miller (22) have suggested that a decreased
sodium load to the macula densa area is the main stimulus
leading to renin release.

However, micropuncture studies by

Thurau and associates (23) have shown that it is an increas-

7
ed delivery of sodium to the macula densa area which is responsible for the observed effects on renin release.

Studies

by Nash et. al. (24) and Humphrey et. al. (25) have supported
this later view.

These data, therefore, can be interpreted

as being suggestive of participation of the macula densa
mechanism primarily in those instances in which renin release
is to be

inhibited.

Alternatively, Barajas (26) has pro-

posed that macula densa influence on renin release is dependent on the degree of distal tubular and afferent arteriolar
contact and that contact increases with increasing tubular
sodium concentration.

Recently, some studies have proposed

that distal tubular chloride load rather than sodium load
may be the stimulus for triggering the macula densa-dependent
effect on renin secretion (27,28,110,111).
2.

Humoral Factors
A large number of circulating factors are known to in-

fluence renin secretion.

Most important among these angio-

tensin II and ADH, and to a lesser degree, ovarian estrogens
and adrenal corticoids.
Infusions of angiotensin II into the renal artery of
dogs have been shown to inhibit renin release (29-32), possibly a direct negative feedback effect on the juxtaglomerular cells or, indirectly through its effect on vascular contractility (31,32).

Blair-West and associates (31) have

demonstrated that chronic intravenous infusion of angiotensin

8

II prevents the rise in plasma renin activity associated with
sodium depletion.

Shade et •. al. (32) have extended these

findings by showing that the inhibitory effect of angiotensin
II on renin secretion is not only seen in the non-filtering
kidney, but it also appears to be independent of renal blood
flow and arterial pressure changes, thus supporting the view
of a direct feedback effect of this agent on renin release.
This concept has received added support by investigators utilizing

~

vitro kidney slice systems (10,33) or the isolated,

perfused rat kidney (34).
ADH has also been postulated to exert an inhibitory influence on renin secretion {30,32,35).

Tagawa and associ-

ates {36) have confirmed these observations by showing that
physiological increases in ADH cause significant decreases
in renin secretion in the unanesthetized sodium-deprived dog.
However, the mechanisms mediating this inhibitory control of
renin release by ADH remains unclear.
The effects of ovarian estrogens and adrenal steroids
on renin secretion have also been investigated.

Oral estro-

genic contraceptives are known to cause variable increases
in plasma renin activity {37) perhaps by their stimulatory
action of hepatic production of renin substrate.

Conversely,

adrenal glucocortocoids may influence renin release through
their actions of renal hemodynamics and glomerular filtration rate (38).

Aldosterone, however, appears to have no

direct influence on renin secretion but it may indirectly

9
affect it by its known action on sodium reabsorption (39).
Recent studies in a number of laboratories have pres.ented evidence supporting the view that prostaglandins

partic~

pate in the control of renin release in normal and pathological states.

Treatment of malignant hypertension with·the

cyclooxygenase inhibitor, indomethacin, has been shown to·
supress plasma renin activity (40).

Administration of ara-

chidonic acid, a prostaglandin precursor, stimulates renin
release in renal cortical slices of the rabbit (41).

PGI 2

has been found to be present in large concentrations in the
renal cortex and to be capable of stimulating renin secretion in both the intact kidney and in renal cortical slices
(41,42).

However, the mechanism involved in the action of

prostaglandins remains to be determined.
3.

Central Nervous Control of Renin Release
It is now clear that a central nervous mechanism parti-

cipates in the peripheral regulation of renin release.

Sti-

mulation of the pons results in dramatic increases in the
rate of renin release in the intact kidney (43-44).

Ueda

et. al. (45) have observed similar increases following mesencephalic stimulation.

Zehr and Feigel (46) have presented

data suggesting the existence of a central inhibitory component as well.

In their studies, they found that stimulation

of the anterior hypothalamus resulted in the suppression of
plasma renin activity in the unanesthetized dog.

These
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results are consistent with the antagonistic roles these
areas playin the regulation of behavior and circulation (47).
In addition to the direct regulatory action of angiotensin II on renin secretion, recent evidence indicates that
it also has a central regulatory role.

Infusions of this

agent into the third cerebral ventricle, are followed by a
decrease in plasma renin activity (16,48).

It is not known

whether this effect may be exerted by angiotensin II generated locally in the brain or alternatively, by systemic angiotensin II which crosses the blood brain barrier.

Regardless,

the possible existence of a functional brain renin angiotensin system is currently the subject of much controversy.
Philips

et. al.

(49) have shown that in addition to angio-

tensin II, other components of the system including renin,
angiotensinogen, and converting enzyme are also present in
brain tissue, thus supporting the existence of a central
renin-angiotensin system.

Conversely, Day and Reid (50) have

suggested that brain •renin" is instead the lysosomal enzyme
cathepsin D.

Additionally, they indicate that the optimum

pH for this so-called brain "renin" enzyme is outside the
physiological range, and that the concentrations of the
other components of the system are too small to be of functional significance.
4.

Peripheral Sympathetic Neural Control of Renin Release
Numerous electron microscopic (51-53) and histo-chemi-

11
cal flourometric studies (54,55), have demonstrated the presence of a large network of nerve terminals in close association with the renal afferent and efferent arterioles and
the juxtaglomerular cells.

These studies have also demon-

strated that these nerve terminals are primarily sympathetic
in nature.

These observations have led to the postulation

that the renal sympathetic nerves may play an important role
in the homeostatic regulation of renin secretion.
a.

Effects of Renal Nerve Stimulation and Renal Denervation

It is generally accepted that the sympathetic nervous
system can influence renin release by both circulating catecholamines from the adrenal medulla and by norepinephrine
secreted by renal sympathetic nerve terminals (39,56).

The

effect of circulating epinephrine and norepinephrine on renin secretion may be indirectly mediated through their actions
on the afferent arteriole baroreceptors, or the macula densa
natrioceptors.

On the other hand, norepinephrine released

by renal sympathetic nerve terminals may directly stimulate
renin release through an interaction with specific receptors
located on the juxtaglomerular cell membrane (10,13).
Evidence for a direct sympathetic effect which is independent of vascular and macula densa influences, has been
gathered from a number of studies.

Johnson et. al.

(57}

showed that electrical stimulation of the renal nerves caused
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an increase in renin release from the non-filtering dog kidney treated with papaverine to inactivate baroreceptor responses.

Similarly, increases in renin release produced by

the stimulation of the vasomotor area of the cat brain are
abolished by renal denervation or treatment with the betaadrenergic blocker, propranolol (44).

Other studies have ad-

ditionally demonstrated that renal nerve stimulation can directly affect renin release in the absence of other factors
{58-60).
Data generated from studies which have utilized the denervated kidney have largely confirmed these findings.
et. al.

Passe

(43) found that the increase in renin release associ-

ated with stimulation of the medulla oblongata, was abolished
by renal denervation.

Denervation has also been shown to

prevent the effects of postural changes and furosemide infusion on renin secretion (61).

Sympathetic effects on renin

release are also blocked by administration of propranolol
(44), by ganglionic blockade or by local anesthesia (30).
b.

Adrenergic Receptor Mediation of Renin Secretion

Numerous in vivo and in vitro studies have shown that
catecholamine administration results in an increase in renin
release (1,2,6,9,10,58,62-67).

Experiments by Otsuka et. al.

(68) in the dog indicate that the marked increase in renin
release caused by insulin-induced hypoglycemia, can be abolished by adrenal denervation and restored by catecholamine

13
infusion.

Thus, these data are indicative of the direct ef-

fect of catecholamines on the renin secreting juxtaglomerular cells.
The stLmulatory effect of catecholamines on renin secretion has been postulated to be mediated by a beta-adrenergic receptor-mechanism (1,2,9,10,69-72), involving intracellular generation of cyclic AMP (1,2,9,10,70-73).
Alternatively, Vandogen et. al.

(74), Nally et. al.

(70) , and Pettinger (75) , have evaluated the role of alphaadrenergic receptors in the control of renin secretion.
Their data show that stimulation of renal alpha-adrenergic
receptors results in a marked inhibition of renin secretion,
which can be prevented by the addition of alpha-blocking
agents.

Moreover, this inhibitory effect on renin release

produced by alpha-adrenergic receptor activation has been
shown to be coupled with significant decreases in the cyclic
AMP content of the renal tissue (9,10,76).
c.

The Dopamine Vascular Receptor and Oopaminergic
Control of Renin Release

It has been amply demonstrated that dopamine is an obligatory precursor of norepinephrine in the central nervous
system and in peripheral sympathetic nerve terminals (77).
It is also known that dopamine is an important central
neurotransmitter (78) and its presence has been reported in
renal tissue (79).

In view of these findings, considerable
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interest has arisen in recent years in regard to the possibility that this catecholamine precursor may participate in
the regulation of renin secretion.

This has been further

strengthened by the findings of a number of investigators
pointing to the existence of a renal dopaminergic receptor
which may mediate renal vascular dynamics
McDonald et. al.

(80~89).

(80,81), have reported that intraven-

ous infusion of dopamine in human subjects, results in marked reduction in renal arterial resistance coupled with a
significant increase in renal plasma flow and sodium excretion.

McNay et. al.

the anesthetized dog.

{82), have observed a similar effect in
Since alpha- and beta-blocking agents

did not alter these responses, they suggested that dopamine
may exert its effect by an alternate receptor mechanism,
possibly one that is dopamine-specific.

The experiments of

Yeh and co-workers (83), in which intrarenal injections of
the dopamine-receptor blocker, haloperidol, attenuated the
renal vasodilating effect of dopamine provided added support
for the existence of a dopamine renal vascular receptor.
Similar results have been obtained using additional dopaminereceptor blockers such as chloropromazine (84), and bulbocapnine (85,86).

Furthermore, the dopamine-receptor agonist

apomorphine and the N-methyl dopamine analog epinine, have
been shown to cause dopamine-like effects on renal vasodilation (87) •
Nakajima and collegues (88,89) have extended these
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findings by suggesting that the action of this dopamine vascular receptor may depend on the activation of an adenylate
cyclase system.

In their studies, addition of dopamine to a

rat kidney particulate preparation resulted in a significant
increase in the cyclic AMP content of the medium, which was
unaffected by alpha- (phentolamine) or beta- (propranolol)
blockade.

Conversely, spiroperidol an effective dopamine-

receptor antagonist, blocked this stimulatory effect while
the dopamine-receptor agonist apomorphine potentiated it.

A

subsequent study by the same investigators {89) confirmed
their original observations and further demonstrated that,
the increased cyclic nucleotide levels produced by addition
of the phosphodiesterase inhibitor theophylline, were effectively blocked by spiroperidol.

Taken together, these find-

ings support the existence of a dopamine-specific, adenylatesensitive, vascular receptor in the kidney.

This is consis-

tent with other evidence suggesting the presence of similar
cyclic AMP-mediated dopamine receptors in the brain and retina (90-92).

In view of the previously discussed data re-

garding the role of dopamine in the regulation of renal vascular dynamics, a number of studies are presently being directed toward determining whether dopamine may have a direct
effect on the juxtaglomerular cells to increase renin secretion, and thus indirectly regulate electrolyte, blood volume,
and blood pressure homeostasis.
Working

~ ~~

Ayers and collegues (62) have shown

16

that dopamine administration results in a marked increase in
renin release.

Bell and Lang (93) have also demonstrated

that dopamine can stimulate renin secretion and that this
effect is blocked by the dopamine-receptor antagonist, ergometrine.

Wilcox et. al.

(65), as well as Imbs and collegues

{94,95), have confirmed these observations.

On the other hand, some studies have provided contradictory evidence.

Cuche et. al.

(96) found an inverse rela-

tionship between urinary dopamine and plasma renin activity,
as a result of postural changes from the supine to the upright position.

Since plasma renin activity increased while

urinary dopamine decreased, they suggested a possible inhibitory role for dopamine on renin release, mediated by changes
in renal plasma flow or sodium load to the macula densa.
Chokshi and associates (97), have supported this concept by
showing that renal artery infusion of dopamine causes an increase in renal plasma flow and a simultaneous decrease in
renin secretion.
In vitro studies generally supported the view of a direct action of dopamine on renin release.

Henry and co-work-

ers (3) have demonstrated in a rat renal cortical preparation, that administration of dopamine doses of 10- 7 M or
greater results in significant increases in renin secretion.
They also found that alpha-receptor blockade (phentolamine},
dopamine-receptor blockade (haloperidol) , or addition of cocaine (a catecholamine re-uptake inhibitor}, did not alter
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the stimulatory effect of dopamine, but that propranolol administration effectively prevented it.

They concluded that

renin release may be partially regulated by a beta-adrenergic mechanism, and that dopamine-specific receptors may not
participate in this regulation.
supported by Quesada et. al.

(4).

Their findings have been
SLmilar in vitro studies

in our laboratory (1,2) have confirmed Henry's and Quesada's
observations in regard to the stimulatory effect of dopamine
on renin release and the inhibition of this effect by propranolol.

However, we have further extended their observations

by demonstrating that both, the stimulatory effect on release
and the blockade of this effect by propranolol, are coupled
with corresponding changes in the cyclic AMP content of the
sliced tissue.

These data strongly support the view that

the action of dopamine on renin secretion, similar to that
exerted by norepinephrine, is mediated by the activation of
an adenylate cyclase receptor complex in the membrane of the
juxtaglomerular cells.

Also, since the data regarding the

possible participation of dopamine-specific receptors is
controversial at best, it is clear that further studies designed to investigate this possibility are in order.

CHAPTER III
MATERIALS AND METHODS
Male, Sprague-Dawley rats (Sprague-Dawley co.) with initial weights of 210 ± lOg, were fed a sodium deficient diet
(Teklad Test Diet Co.) providing less than 0.02mEq of sodium
per day for 1.5 to 2.5 weeks.

Male animals were chosen to

eliminate the influence of cyclic estrogenic variations, in
view of reports that circulating estrogens can exert effect
on renin release (37).

They were kept in a temperature-con-

trolled room, two animals per cage and had unlimited access
to distilled-deionized water.

At the end of the dietary in-

take period, the animals were sacrificed by decapitation and
their kidneys rapidly excised, gassed for 30 sec with 95% o

2

- 5% co 2 prior to and after decapsulation, and placed in
Robinson's buffer medium (98) at 4°C.

Renal cortical slices

approximately 0.3mm thick were prepared using a Stadie-Riggs
microtome (A. Thomas Co.).

Each cortical slice was further

divided into several portions according to the number of
treatments, and randomly assigned to separate incubating
vessels containing 2.5 ml of Robinson's buffer.

This pro-

cedure was repeated using other areas of the renal cortex
until each vessel contained 50 ± 30mg of cortical tissue.
18
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This random distribution of sliced tissue ensured that all
incubating vessels contained a homogeneous cell population
from each cortical area, and thus allowed one of each group
to be used as a common untreated control for each group of
treatments.

The tissue was then pre-incubated for 15 min at

37°C in a shaking Dubnoff Metabolic Incubator (Precision
Scientific), in an atmosphere saturated with 95%

o2

- 5%

co2 •

The pre-incubated slices were subsequently transferred to
corresponding incubating vessels containing 2.5 ml of Robinson's buffer previously equilibrated to 37°C, and incubated
for 5, 20 or 60 min, under conditions identical to those of
the pre-incubation period.
A group of experimental vessels, having a common control
sample, was treated with dopamine (10- 3M) added either alone
or together with either of two doses of the dopamine-receptor
blocker pimozide (10- 8M or 10- 6M). Pimozide at both concentrations was also added alone to the renal cortical preparation.

Alternatively, a second group of vessels was similarly
treated with 10- 3M dopamine, but in this instance the dopamine-receptor agonist apomorphine (10- 6M) was added to the
slice system either alone or together with dopamine.

All

tissue samples, including controls, were also treated with
4
the dopamine beta-hydroxylase inhibitor FLA-63 (10- M) to
prevent conversion of dopamine to norepinephrine (99) in the
slice preparation.

FLA-63, apomorphine, and pimozide, were

added to the tissue system prior to both the pre-incubation
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and incubation periods whereas, dopamine was added prior to
the incubation period only.
Dopamine (Sigma), apomorphine, and FLA-63 (Regis Chemical Co.) solutions were prepared in 0.1% ascorbic acid (Sigma) to prevent oxidation.

Pimozide solution (Janssen Phar-

maceutical) were prepared in 1.2% tartaric acid (Sigma) for
the same reason.
Following incubation, the supernatant medium was collected and stored at -20°C until assayed for renin concentration.

Tissue used for cyclic

&~P

determination was collected

at the end of all incubation periods and rapidly frozen on
dry ice.

The frozen tissue was then homogenized in 1 ml of

8% trichloroacetic acid and stored at -20°c.
A.

Tissue Cyclic AMP Extraction and Measurement of its
Content
Frozen cyclic AMP tissue homogenates were allowed to

thaw in an ice-water bath, followed by centrifugation at
3100g for 10 min at 4°c.

The supernatant was transferred to

conical centrifuge tubes using disposable Pasteur pipettes
while the protein-containing precipitate was discarded.

The

supernantant samples were then washed four times with 2 ml
of water-saturated ether, vortexed for 10 sec at each step,
and the ether phase aspirated and discarded.

After the fi-

nal wash, the cyclic AMP-containing water phase was

decante~

into glass vials previously placed on dry ice for rapid
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freezing.

The frozen samples were lyophilized and the fre-

eze-dried residue was stored at -20°C until assayed for cyclic AMP content.
Cyclic AMP content of the freeze-dried material was
measured by a modification of the competitive protein-binding
assay of Gilman (100).

The results were expressed as pice-

moles of cyclic AMP per mg of wet tissue.
B.

Purification of Tissue Renin
Samples collected for determination of tissue renin con-

tent were homogenized in 1 ml of 0.9% sodium chloride (physiological saline) at 4°C, and centrifuged for 15 min at
3500g.

The supernatant was dialyzed for 24 hrs at 4°C

against an EDTA-saline buffer at pH 3.3, followed by heating
to 32°C for one hour to denature any endogenous renin substrate or angiotensinases, and then dialyzed again for 24
hrs at 4°C against an EDTA-phosphate buffer at pH 7.5 (101).
The purified supernatant samples were then stored at -20°c
until assayed for renin concentration by radio-immunoassay
of angiotensin I.
c.

Angiotensin I Generation and Measurement
Renin concentration in both the dialyzed purified and

the incubated supernatant samples, was indirectly measured
by determining the rate of angiotensin I generation produced
by endogenous renin present in our samples upon exposure to

22
exogenous substrate (angiotensinogen) obtained from 4 hr nephrectomized dog plasma (102).

An inhibitor of converting

enzyme and angiotensinases was used to prevent

~~y

further

conversion of the angiotensin I generated during a one hour
incubation period at 37°C.

Briefly, both the dialyzed and

incubated supernatant samples were allowed to thaw, vortexed
for ten seconds and maintained at 4°C in an ice-water bath.
Aliquots of 0.025 ml from each sample were transferred to
test tubes at 4°c.
and

o.s

Five drops of saturated sodium chloride,

ml of 4 hr nephrectomized dog plasma previously

treated with the converting and angiotensinase inhibitor,
phenyl methyl sulfonyl flouride (PMSF, Sigma, 0.05 ml per ml
plasma) , were added to each tube.

The samples were then in-

cubated for one hour at 37°c, diluted 1:2 with distilled-deionized water, vortexed, and then placed in a boiling water
bath for 3 min to stop further generation of angiotensin I.
The samples were allowed to cool and then stored at -20°C
until assayed.
Renin concentration in all samples was then determined
by

radio~unoassay

of angiotensin I in the generated samples

(New England Nuclear).

The results were expressed as nano-

grams of angiotensin I generated per mg of wet tissue per
hour.
Statistical significance of the data was evaluated by
Student's paired and unpaired t-tests and Linear Regression
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Analysis using a programmable desk-top calculator (HewlettPackard).

RESULTS
Resting renin release rate and tissue cyclic AMP content of renal cortical slices from sodium deficient rats
were initially evaluated in relation to the length of incubation time (Fig. 1}.

Renin release rate from these con-

trol tissue samples was linear with time of incubation (p

<

0.0005}, which would be expected of metabolically active endocrine tissue.

In contrast, cyclic AMP content was maximal

by 20 min of incubation and then decreased to a level similar
to that seen at 5 min by the end of a one hour incubation
period.
Renin release and tissue cyclic AMP content responses
to 10- 3M dopamine administration were subsequently examined
and compared to those of non-treated control samples (Fig. 2).
These data show that the mean renin release rate of the dopamine-treated samples appeared to be higher than that of
controls at 5 min and 20 min, and was significantly greater
by 60 min.

Similarly, corresponding tissue cyclic AMP levels

were significantly greater than those of controls as early
as 5 min.

Tissue renin levels in dopamine-treated samples

were not different from those of controls at 60 min.
24
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To further evaluate the type of mechanism mediating the
stimulatory effect of dopamine on renin release, an experiment was designed to examine the effect of the dopamine-receptor agonist apomorphine, added alone or together with
dopamine, on renin secretion, tissue cyclic AMP content, and
tissue renin content (Fig. 3).

In the presence of 10- 6 M apo-

morphine, dopamine was no longer capable of stimulating ren-

in release or tissue cyclic AMP content levels in our cortical preparation.

Apomorphine by itself did not affect renin

release but it did stimulate cyclic AMP content at 60 min.
Mean tissue renin content changes in the presence of dopamine
plus apomorphine were consistent with those seen in renin
release and cyclic AMP content.
An additional study was undertaken to provide further

evidence regarding the mechanism by which the dopamine-receptor blocker pimozide stimulates renin secretion as previously
reported (1,2).

In this study, the effect of pimozide alone

or together with dopamine, on renin release, tissue cyclic
AMP content, and tissue renin content was examined in relation to the time of incubation (Fig. 4).

The data show that

two doses of pimozide (10- 8 M and 10- 6 M) added to the tissue
preparation, caused a significant increase in renin release
coupled with a significant decrease in tissue cyclic AMP
content during a one hour incubation period.

These changes

were seen whether dopamine was present or not, suggesting
the the effect was due to pimozide itself.

In addition, the
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mean tissue renin content appeared decreased by the
stration of pimozide when compared to controls.

a~~ini

When the

renin release, tissue renin content, and tissue cyclic AMP
content responses to both pimozide doses were evaluated in
regard to time of incubation (Fig. 5), the significant stimulatory effect of this agent on renin release and its simultaneous marked inhibition of cyclic AMP content were evident
as 5 min of incubation.

At 60 min, mean tissue renin content

of pimozide-treated samples appeared to be lower than that
of controls.

Furthermore, the renin release and tissue ren-

in content changes caused by pimozide administration appeared dose-dependent, whereas those seen in tissue cyclic AMP
content were similar in magnitude regardless of the dose
used.
Fig. 6 depicts the results of our study with dopamine
and apomorphine, and those generated in a parallel study utilizing the dopamine-receptor blocker d-butaclamol and the
phosphodiesterase inhibitor theophylline.

The implication

of the significant stimulation of renin release and tissue
cyclic AMP content seen in the presence of dopamine, theophylline or d-butaclamol, and the corresponding inhibition
of the stimulatory effect of dopamine on these parameters
caused by apomorphine administration is discussed in the
next section.
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Figure 1

.
>

Resting renin release rate and tissue cyclic

&~P

in renal cortical slices from sodium deficient rats.

levels
The

data represent the mean renin release rate ± S.E. of 14 - 32
k~P

level ± S.E. of

12 - 14 observations at 3 incubation times.

The mean rest-

observations and the mean tissue cyclic

ing renin release rate at S, 20, and 60 min of incubation
was 2.55

~

0.28ng/mg/hr, 3.86 ± o.80ng/mg/hr, and 10.28 ±

l.Olng/mg/hr, respectively.

The corresponding mean resting

tissue cyclic AMP levels were, 0.397 ±

0.032~nol/mg,

0.076pmol/mg, and 0.436 ± 0.046pmol/mg, respectively.

0.616 ±
The

DBH inhibition FLA-63 (10- 4 M) was added to all samples u~
this and subsequent experiments.
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Figure 2
Renin release rate, tissue cyclic AMP content, and tissue renin content responses to 10- 3 M dopamine added to renal
cortical slices from sodium deficient rats.

The data repre-

sent the mean renin release rate ± S.E. of 14 - 32 observations, the mean tissue cyclic AMP content ± S.E. of 12 - 14
observations, and the mean tissue renin content ± S.E. of 23
observations at 3 incubation times.

The mean control (un-

treated} renin release rate and tissue cyclic AMP content
values are the same as those described in Fig. 1.

Mean con-

trol tissue renin content at 60 min was 1419 ± 103ng/mg/hr.
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Figure 3
Changes in renin release, tissue cyclic AMP content,
and tissue renin content, in response to 10- 3 M dopamine and
10

-6 M

.

apomorph~ne,

added separately or together to renal

cortical slices from sodium deficient rats.

The data repre-

sent the mean renin release change ± S.E. of 7 - 15 observations, the mean tissue cyclic AMP content change ± S.E. of
7 - 8 0bservations, and the mean tissue renin content change
± S.E. of 24 observations for each treatment at 3 incubaticn

times.

The mean control (untreated) renin release rate at

5, 20, and 60 min of incubation was 2.56 ± 0.48ng/mg/hr,
4.69 ± 1.5lng/mg/hr, and 10.60 ± 1.39ng/rng/hr, respectively.
The corresponding mean control cyclic AMP content values
were, respectively, 0.39 ± 0.033pmol/rng, 0.527 ± 0.094pmol/
mg, and 0.453 ± 0.072pmol/mg.

Mean control tissue renin

content at 60 min was 489ng/mg/hr.
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Figure 4
Renin release, tissue cyclic AMP content, and tissue
renin content responses to 10- 3M dopamine, added along or
together with 10- 8M or l0- 6H pimozide to renal cortical
slices from sodium deficient rats.

The data represent the

mean renin release rate ± S.E. of 11 observations, the mean
tissue cyclic AMP content ± S.E. of 9 observations, and the
mean tissue renin content ± S.E. of 11 observations, for
each treatment during a 60 min incubation period.

The mean

control (non-treated) renin release rate was 14.2 ± 3.6lng/
mg/hr, mean control

cyclic.~

content was 0.794 ± O.l94pmol/

mg, and mean control tissue renin content was 3833 ± 866ng/
mg/hr, respectively.
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Figure 5
Changes in renin release, tissue cyclic

&~

content,

and tissue renin content, in response to two doses of pimozide added separately to a renal cortical slice preparation
from sodium deficient rats.
in release change ±
c~clic ~~W

The data represent the mean ren-

s.E. of 11 observations, the mean tissue

content change ± S.E. of 6 - 9 observations, and

the mean tissue renin content change ± S.E. of 11 observations for each treatment at 3 incubation times.
control (non-treated) renin release rate at

s,

The mean
20, and 60

min of incubation was 3.38 ± 0.88ng/mg/hr, 8.84 ± l.97ng/mg/
hr, and 14.2 ± 3.6lng/mg/hr, respectively.

ing mean control cyclic

&~P

The correspond-

content values were, respective-

ly, 0.767 ± O.l76pmol/mg, 1.14 ± 0.33pmol/mg, and 0.794
O.l94pmol/mg.

±

Mean control tissue renin content at 60 min

was 3833 ± 866ng/mg/hr.
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Figure 6
Changes in renin release, tissue 'cyclic AMP content,
3
and tissue renin content in response to 10- M dopamine added
alone or together with 10- 3 M theophylline, 10- 6 M d-butacla6
mol, or 10- M apomorphine, to renal cortical slices from sodiurJ deficient rats.
lease

ch~'ge

±

s.E.

The data represent the mean renin reof 2 - 18 observations, the mean tissue

cyclic AMP content change ± S.E. of 2 - 12 observations, and
the mean tissue renin content change ± S.E. of 9 - 24 observations for each treatment at 3 incubation times.

The mem1

control (non-treated) values for treatments involving dopamine alone or together with theophylline and d-butaclamol
at 5, 20, and 60 min

o~

incubation were, respectively, 2.55

± 0.276, 3.86 ± 0.801, and 10.28 ± l.Olng/mg/hr for,renin

release1

0.397 ± 0.032, 0.616 ± 0.076, and 0.437 ± 0.046

pmol/mg for cyclic

&~

content; and 1419 ± 303ng/mg/hr for

tissue renin content at 60 min.

The corresponding mean con-

tr.ol values for treatments involving dopamine alone or together with apomorphine in regard to the same 3 parameters
at

s,

20, and 60 min, are the the same as those described in

Figure 3.
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DISCUSSION
The use of an in vitro renal cortical slice system in
this study allowed an effective evaluation not only of the
effect of isolated stimuli on renin release, but also of the
dynamics of renin secretion in resting tissue in relation to
time.

Investigators utilizing this type of renal prepara-

tion have demonstrated that in resting renal tissue (11,103),
renin secretion is an active process which is linear with
time.

The data generated in the present study, utilizing

the sodium deficient rat (Fig. 1), clearly support this view.
Dopamine has been shown to stimulate in vitro renin secretion by a beta-adrenergic receptor mechanism (1,2,3,4)
mediated by tissue cyclic AMP changes (1,2).

Our data sup-

ports these observations by demonstrating that the significant stimulatory effects exerted by dopamine on renin release after one hour of incubation (Fig. 2), was preceded by
a significant increase in tissue cyclic AMP content as early
as 5 min of incubation.

This view is further supported by

data from a parallel study in our laboratory (12), which
show that addition of the phosphodiesterase inhibitor, theophylline, to our cortical preparation, significantly poten39
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tiates the renin release and tissue cyclic AMP content responses to dopamine (Fig. 6).
Although the mean tissue renin content of our dopaminetreated samples was not significantly different from that of
controls (Fig. 2), it was greater in magnitude, suggesting
the possibility of renin synthesis in response to dopamine
administration.

Data from parallel studies utilizing_ theo-

phylline (Fig. 6) are consistent with this possibility since
the mean tissue renin content responses to dopamine administration were potentiated when theophylline was simultaneous-

of previous studies

ly added to our in vitro system.

This agrees with a number

reporting that catecholamine administra-

tion stimulates renin synthesis as well as renin secretion.
For instance, addition of norepinephrine or epinephrine has
been reported to increase tissue renin content in renal preparations from cats (73) and that this effect is prevented
by administration of the protein inhibitor, cyclohexamide.

The use of radioactively labeled amino acids in monitoring
:.new renin synthesis in response to sympathetic stimuli, has

recently confirmed these findings (104).
The concept of a specific renal dopaminergic receptor
mediating the stimulatory effect
viously proposed (105,106).

pre-

The results of our study utili-

zing the dopamine-receptor agonist, apomorphine (Fig. 3),
do not agree with this view.

Instead, they suggest that dop-

amine may exert an inhibitory effect on renin release via
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a cyclic AMP-mediated--dopamine-specific receptor mechanism,
as indicated by the fact that apomorphine prevented the stimulatory effect of dopamine on renin release and tissue cyclic
AMP content.

The observation in a parallel study (Fig. 6) on

the potentiation of dopamine-induced renin release by the dopamine-receptor blocker, d-butaclamol, offers further support
for the concept of dopamine-receptor mediated inhibition of
renin release.

Thus, our data suggest that dopamine may exert

a dual regulatory control on renin secretion, namely a stimulatory one through a beta-adrenergic receptor mechanism and
an inhibitory one via a dopamine-receptor pathway.

This is

not surprising, since dopamine has been reported to have the
molecular flexibility required to effectively bind to structurally different receptors (107).

However, the physiologic-

al significance of this dual regulation of renin secretion by
dopamine is unclear.

A similar type of control has been pre-

viously proposed in regard to the effect of norepinepherine
on renin secretion (9,10,74,75).

Recently, Quesada et. al.

(4), have reported results similar to those seen in our study,
although the significance of the potentiation of renin release
observed upon administration of the dopamine-receptor blocker,
haloperidol, was not discussed.

In hibitory effects by dop- -

amine, which appear to be mediated by dopamine-specific receptors, have also been demonstrated in regard to aldosterone
(108), episodic luteinizing hormone (109) , and prolactin re-
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lease ( 112) •
Data from the present study (Fig. 4) confirm previous
in vitro observations in our laboratory (1,2) in regard to
the significant effect exerted by the dopamine-receptor
blocker, pimozide, on renin release and tissue cyclic AMP
content during a one our incubation period.

The significant

stimulatory effect on renin release and the simultaneous depression of cyclic AMP content caused by the administration
of this agent in previous

studies, was confirmed in this

study utilizing two additional doses.

Furthermore, this

dissociation of the renin release and tissue cyclic AMP responses to pimozide administration, occurred whether or not
dopamine was

s~ultaneously

was due to pimozide itself.

added, suggesting that the effect
Our results (Fig. 4) have ex-

tended our previous observations by showing that tissue renin
content at 60 min appeared decreased in relation to controls,

--

suggesting an inhibition of de novo synthesis.

The results

of a subsequent experiment (Fig. 5), which examined the effects of pimozide on renin release, cyclic AMP content, and
tissue renin content in relation to time, suggest that the
action of this agent on these parameters is not mediated by
a physiological mechanism, but rather by a toxic effect exerted on the membrane of the renin-secreting cells.

This view

is supported by our observation that the rate of renin release in response to pimozide was markedly increased as early
as 5 min, suggesting that pre-formed renin was being prefer-
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entially released, perhaps due to the alterations in juxtaglomerular cell membrane permeability.

Furthermore, the de-

creased levels in tissue cyclic AMP and tissue renin content
seen in our study, are consistent with the view that pharmacological toxicity will inactivate membrane-bound adenylate
cyclase systems.

Pharmacological changes in membrane struc-

ture and permeability leading to uncontrolled renin release,
have also been postulated to be important in the stimulatory
effect exerted by the beta-receptor agonist isoproterenol
(66), perhaps involving changes in tissue cyclic AMP and tissue renin content similar to those seen in our study.

This

possibility however, cannot be confirmed, since these investigators only evaluated changes in renin release.

In view

of reports (95) questioning the specificity of pimoiide as a
dopamine receptor blocker in peripheral organ systems, it is
clear that specific dopamine-receptor antagonists need to be
used in order to effectively evaluate the possibility that
dopamine receptors participate in the regulation of renin
secretion from the mammalian kidney.
In summary, the data reported in this paper support the
concept that dopamine may regulate renin secretion by two
distinct receptor mechanisms involving changes in tissue cyclic AMP levels.

Activation of beta-adrenergic receptors

mediates its stimulatory effect (2) , while its inhibitory
action may be exerted through
(12).

dopamine-specific receptors

Additionally, these results clearly suggest that pim-
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ozide-stimulated renin release may be the consequence of
adenyl cyclase inactivation induced by a generalized toxic
effect exerted by pimozide on the juxtaglomerular cell membrane, leading to alterations in its permeability.
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